press release

Aug. 6, 2020, 6:56 a.m. EDT

Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020

GAITHERSBURG, Md., Aug 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- GAITHERSBURG, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. /zigman2/quotes/202614340/composite NVAX -6.19% , a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, August 10, 2020.

Conference call details are as follows:

Date: August 10, 2020
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 923-9376 (Domestic) or (720) 545-0026 (International)
Passcode: 3048947
Webcast: www.novavax.com , "For Investors"/ "Events"

Conference call and webcast replay:

Dates: Starting at 7:30 p.m. ET, August 10, 2020 until 7:30 p.m. ET August 17, 2020
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 3048947
Webcast: www.novavax.com , "For Investors"/ "Events", until November 10, 2020

About Novavax

Novavax, Inc. /zigman2/quotes/202614340/composite NVAX -6.19% is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NVX�?'CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in its Phase 1 portion of the Phase 1/2 clinical trial. NanoFlu(TM), its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M(TM) adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn .

Contacts:
InvestorsSilvia Taylor and Erika Trahan
ir@novavax.com240-268-2022

Media
Amy Speak
amy@speaklifescience.com 617-420-2461


COMTEX_368968802/2471/2020-08-06T06:55:46

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2020 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 108.36
-7.15 -6.19%
Volume: 5.82M
Sept. 18, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$7.08 billion
Rev. per Employee
$90,470
loading...
/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 108.36
-7.15 -6.19%
Volume: 5.82M
Sept. 18, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$7.08 billion
Rev. per Employee
$90,470
loading...

Link to MarketWatch's Slice.